Dr Simon Brackenridge
Senior Postdoctoral Researcher
After graduating with a BSc in Molecular Biology from the University of Edinburgh, I moved to Oxford to take up a D.Phil under the supervision of Nicholas Proudfoot at the Sir William Dunn School of Pathology, studying eukaryotic transcription termination and polyadenylation. Following completion of my thesis, I remained as a post-doctoral researcher in the Proudfoot laboratory for two years, before moving to the Weatherall Institute of Molecular Medicine, studying alternative splicing of an atypical 5' splice site in the human Fibroblast Growth Factor Receptor genes with Gavin Screaton. I then joined the group of Professor Sir Andrew McMichael, initially helping develop a new microarray platform in collaboration with Oxford Gene Technology, before moving on to projects on HLA-C expression, and 3 domain Killer Immunoglobulin-like Receptors (KIRs). For the last few years, my work has focused on the molecular biology of MHC-E, part of a collaboration with Louis Picker (Oregon Health and Science University). In addition to using cellular assays to understand the binding of noncanonical peptides by MHC-E, I am also investigating the host factors required by human and rhesus macaque Cytomegaloviruses for the maintenance of HLA-E expression following disruption of both the peptide processing pathway and classical MHC Class I expression. On a more general level, I also provide molecular biology support for both the McMichael and Borrow groups.
Mapping the epitopes of the Human Leukocyte Antigen E antibodies 3D12 and 4D12
Brackenridge S. et al, (2022)
Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity.
Li D. et al, (2022), Commun Biol, 5
HLA-E–restricted, Gag-specific CD8
T cells can suppress HIV-1 infection, offering vaccine opportunities
Yang H. et al, (2021), Science Immunology, 6
HLA binding of self-peptides is biased towards proteins with specific molecular functions
Karnaukhov V. et al, (2021)
HLA-E restricted, HIV-1 suppressing, Gag specific CD8+ T cells offer universal vaccine opportunities
Yang H. et al, (2020)